ZBIO

Zenas Biopharma Stock Analysis

AI Rating

Low
  • Quality6/10
  • Growth↓ 4/10
  • Value↓ 0/10
Zenas Biopharma sales and earnings growth
ZBIO Growth
Neutral
  • Revenue Y/Y↑ 100.00%
  • EPS Y/Y↑ 29.02%
  • FCF Y/Y↓ -43.86%
Zenas Biopharma gross and profit margin trends
ZBIO Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -3777.40%
  • ROIC 5Y↓ 0.00%
Zenas Biopharma net debt vs free cash flow
ZBIO Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -50.6

Zenas Biopharma stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗